Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have studied the immune response of 34 adult participants from the first phase of a clinical trial. These include the young to the elderly.
Washington: Corona virus (Coronavirus) between the pandemic vaccine in many countries on the front (COVID-19 Vaccine) are working increasingly closely with vaccine companies. Moderna’s corona vaccine has been found to be 94 percent effective. A study on Moderna’s vaccine said on Thursday that Moderna’s COVID-19 Vaccine produces powerful antibodies (antibodies) in the human immune system that last for at least three months.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have studied the immune response of 34 adult participants from the first phase of a clinical trial. These include the young to the elderly. NIAID together with Moderna has developed the vaccine.
Also Read: The CDC said that the virus of cry had reached America before China
Researchers have stated in the New England Journal of Medicine that the level of endibodies that prevent the SARS-CoV-2 virus from invading human cells has remained elevated in all participants up to three months after the vaccine. However, AndyBody’s numbers saw a slight decline over time, which was expected. ”
Also Read: Good news on corona vaccine, vaccination program to begin in US on December 11 or 12
The vaccine, also known as mRNA-1273, was given to people with two injections at intervals of 28 days. The study says that even though the number of endobodies has decreased over time, it is not necessarily a cause for concern.
